Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 135 The West Mall, Unit 2 TORONTO ON M9C 1C2 |
Tel: | 1-416-9623300 |
Website: | https://spectraldx.com |
IR: | See website |
Key People | ||
Paul M. Walker Chairman of the Board, President | Chris Seto Chief Executive Officer, Director | John Kellum Chief Medical Officer |
Business Overview |
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's EAA. PMX has been on the market in many countries outside the United States and has been used in more than 340,000 patients to date. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It is also continuing its legacy business of manufacturing and selling certain reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies. |
Financial Overview |
For the fiscal year ended 31 December 2023, Spectral Medical Inc revenues decreased 4% to C$1.6M. Net loss before extraordinary items increased from C$7.6M to C$15.5M. Revenues reflect Other segment decrease of 72% to C$90K, Italy segment decrease of 22% to C$246K. Higher net loss reflects Consulting and professional fees increase of 82% to C$4.8M (expense), Fair Value Adjustment Derivative Liabili increase from C$0K to C$1.6M (expense). |
Employees: | 29 as of Dec 31, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $128.21M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.60M as of Dec 31, 2023 |
EBITDA (TTM): | -$11.51M as of Dec 31, 2023 |
Net annual income (TTM): | -$15.51M as of Dec 31, 2023 |
Free cash flow (TTM): | -$10.91M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $5.61M as of Dec 31, 2023 |
Shares outstanding: | 278,644,428 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |